Dentons Turkish affiliate Balcioglu Selcuk Ardiyok Keki Attorney Partnership has advised Koc Medical on its acquisition of Bicakcilar Global Tibbi Urunler and its fully owned subsidiary Bicakcilar Tibbi Cihazlar.
B2RLaw and DZP Advise on Vinci HiTech Fund Investment into Oasis Diagnostics
B2RLaw has advised the Vinci HiTech ASI fund on its nearly PLN 14 million investment into Polish medical technology start-up Oasis Diagnostics. Domanski Zakrzewski Palinka advised Oasis Diagnostics.
Weinhold Legal Advises Eureking on Acquisition of SCT Cell Manufacturing from PPF Group
Weinhold Legal has advised Eureking on the acquisition of SCT Cell Manufacturing from PPF Biotech.
Major Legislative Changes in Hungary's Pharma and Food Industry
Significant legal changes occurred in the Hungarian pharmaceutical and food industry in the summer of 2023. According to Government Decree No. 333/2023. (VII. 20.), as of 1 August 2023, the National Public Health Centre (NNK) and the National Institute of Pharmacy and Nutrition (OGYÉI) merged, establishing a new authority, the National Centre for Public Health and Pharmacy (Nemzeti Nepegeszsegugyi es Gyogyszereszeti Kozpont, NNGYK).
Reform of the Pharmaceutical Sector Taking Shape in Kosovo: A New Law on the Pricing of Medicinal Products Approved
Kosovo has recently adopted a new law to regulate the pricing of medicinal products (Law on Pricing of Medicinal Products). This marks the first time that Kosovo has taken steps to regulate the pricing of medicinal products, and it is a significant milestone in an upcoming major reform within the healthcare and pharmaceutical sector. The reform also includes new laws on medicinal products and medical devices, health insurance, and related areas.
The Debrief: August 2023
In The Debrief, our Practice Leaders across CEE share updates on recent and upcoming legislation, consider the impact of recent court decisions, showcase landmark projects, and keep our readers apprised of the latest developments impacting their respective practice areas.
Protection of Personal Data in Clinical Trials
May 2023 marks five years since the application of the General Data Protection Regulation, better known as "GDPR", and its requirements still pose a number of challenges for organizations. On one hand, this is because ensuring compliance with GDPR is not a "one-time exercise" but a continuous process "from within", requiring synchronization with all other activities in the organization. On the other hand, companies must also take into consideration innovations "from the outside", including new regulations and technologies, by promptly addressing data protection risks.